WO2011039675A3 - Latrepirdine transdermal therapeutic dosage forms - Google Patents

Latrepirdine transdermal therapeutic dosage forms Download PDF

Info

Publication number
WO2011039675A3
WO2011039675A3 PCT/IB2010/054241 IB2010054241W WO2011039675A3 WO 2011039675 A3 WO2011039675 A3 WO 2011039675A3 IB 2010054241 W IB2010054241 W IB 2010054241W WO 2011039675 A3 WO2011039675 A3 WO 2011039675A3
Authority
WO
WIPO (PCT)
Prior art keywords
latrepirdine
dosage forms
transdermal therapeutic
therapeutic dosage
transdermal
Prior art date
Application number
PCT/IB2010/054241
Other languages
French (fr)
Other versions
WO2011039675A2 (en
Inventor
Jeremy Adam Bartlett
Brendan John Murphy
Gautam Ramachandra Ranade
Thean Yeow Yeoh
Jr. Carl Bernard Ziegler
Susan Wollowitz
Sheila Matz
Original Assignee
Pfizer Inc.
Medivation Neurology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Medivation Neurology, Inc. filed Critical Pfizer Inc.
Publication of WO2011039675A2 publication Critical patent/WO2011039675A2/en
Publication of WO2011039675A3 publication Critical patent/WO2011039675A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides transdermal formulations comprising latrepirdine or pharmaceutically acceptable salts thereof having desirable pharmacokinetic characteristics. Also provided are novel transdermal compositions and their manufacture.
PCT/IB2010/054241 2009-09-30 2010-09-20 Latrepirdine transdermal therapeutic dosage forms WO2011039675A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24726309P 2009-09-30 2009-09-30
US61/247,263 2009-09-30
US37486810P 2010-08-18 2010-08-18
US61/374,868 2010-08-18

Publications (2)

Publication Number Publication Date
WO2011039675A2 WO2011039675A2 (en) 2011-04-07
WO2011039675A3 true WO2011039675A3 (en) 2011-12-29

Family

ID=43826724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054241 WO2011039675A2 (en) 2009-09-30 2010-09-20 Latrepirdine transdermal therapeutic dosage forms

Country Status (1)

Country Link
WO (1) WO2011039675A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534523B2 (en) 2011-08-30 2022-12-27 Avery Dennison Corporation Silicone absorbent adhesive layer
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
WO2017153441A1 (en) * 2016-03-09 2017-09-14 Tesa Labtec Gmbh Topical composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2007087425A1 (en) * 2006-01-25 2007-08-02 Medivation Neurology,Inc. Methods and compositions for treating schizophrenia
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008147551A1 (en) * 2007-05-25 2008-12-04 Medivation Nuerology, Inc. Methods and compositions for stimulating cells
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2010068480A1 (en) * 2008-11-25 2010-06-17 Concert Pharmaceuticals, Inc. Deuterated derivatives of dimeboline

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180599T3 (en) 1994-09-30 2003-02-16 Mika Pharma Ges Fur Die Entwic PHARMACEUTICAL COMPOSITION
RU2106864C1 (en) 1995-10-23 1998-03-20 Николай Серафимович Зефиров New approach to treatment of alzheimer's disease
EP1937263A2 (en) 2005-10-04 2008-07-02 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20060018839A1 (en) * 2002-05-17 2006-01-26 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2007087425A1 (en) * 2006-01-25 2007-08-02 Medivation Neurology,Inc. Methods and compositions for treating schizophrenia
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008147551A1 (en) * 2007-05-25 2008-12-04 Medivation Nuerology, Inc. Methods and compositions for stimulating cells
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2010068480A1 (en) * 2008-11-25 2010-06-17 Concert Pharmaceuticals, Inc. Deuterated derivatives of dimeboline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RACHEL S. DOODY ET AL, ON BEHALF OF THE DIMEBON INVESTIGATORS ET AL: "Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 372, no. 9634, 19 July 2008 (2008-07-19), pages 207 - 215, XP022938806, ISSN: 0140-6736, [retrieved on 20080717], DOI: 10.1016/S0140-6736(08)61074-0 *
STEELE JOHN W ET AL: "Acute dosing of latrepirdine (Dimebonâ ), a possible Alzheimer therapeutic, elevates extracellular amyloid-Î levels in vitro and in vivo", MOLECULAR NEURODEGENERATION, BIOMED CENTRAL LTD, LO, vol. 4, no. 1, 17 December 2009 (2009-12-17), pages 51, XP021069635, ISSN: 1750-1326 *

Also Published As

Publication number Publication date
WO2011039675A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
HK1152478A1 (en) Solid pharmaceutical formulations comprising bibw 2992
WO2010102071A8 (en) Sustained release oral dosage forms of an r-baclofen prodrug
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2012051559A3 (en) Compositions and methods of treating pulmonary hypertension
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011069076A3 (en) Sustained release donepezil formulations
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
WO2011143469A8 (en) Therapeutic regimens
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2011069032A3 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
WO2011064558A3 (en) Pharmaceutical composition
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
WO2013074871A3 (en) Humanin analogs
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2009019662A3 (en) Oral metaxalone compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10765508

Country of ref document: EP

Kind code of ref document: A2